PCSK9 and lung carcinoma: There are various preclinical studies based on tumour tissue or mouse models that report the direct effects of PCSK9 or PCSK9 inhibitors on multiple types of cancer [57], including hepatocellular carcinoma [58,59], lung carcinoma [60,61], colorectal cancer [62], and breast cancer [63].